We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adjusted earnings were $2.8 per share, outpacing the Zacks Consensus Estimate by 1.1% and rising 14.1% on a year-over-year basis. Total revenues of $3.9 billion surpassed the consensus estimate by 1.1% and grew 4.3% from the year-ago quarter.
The IQV stock has gained 20% over the past year, underperforming the 30% rally of the industry it belongs to and 39.8% growth of the Zacks S&P 500 Composite.
One Year Price Performance
Image Source: Zacks Investment Research
IQVIA’s Quarterly Details
The Research and Development segment’s revenues were $2.2 billion, increasing 1.9% from the year-ago quarter and 2% on a constant-currency basis. This metric met our estimate.
Revenues from the Technology and Analytics segment were $1.6 billion, increasing 8.6% from the third quarter of 2023. The metric beat our estimate of $1.5 billion and increased 8.2% on a constant-currency basis.
Contract Sales & Medical Solutions revenues decreased 1.6% on a year-over-year basis to $180 million and increased 1.1% on a constant-currency basis. It missed our expectation of $182.9 million.
Adjusted EBITDA for the third quarter of 2024 was $939 million, indicating a 5.7% rise from the year-ago quarter and outpacing our projection of $938.6 million.
The company exited the quarter with cash and cash equivalents of $1.6 billion compared with $1.5 billion at the end of the preceding quarter. Long-term debt (less current portion) was $12.3 billion compared with $12.1 billion at the end of the second quarter of 2024.
Net cash generated from operating activities was $721 million and the capital expenditure for the quarter was $150 million. The company generated a free cash flow of $571 million in the quarter.
IQV’s 2024 Guidance
For 2024, IQVIA lowered its revenue guidance to $15.35-$15.40 billion from the $15.43-$15.53 billion mentioned in the previous quarter. The Zacks Consensus Estimate of $15.46 billion is higher than IQV’s revised guided range.
The company updated the adjusted EPS guidance to $11.10-$11.20 from the $11.10-$11.30 given in the previous quarter. The mid-point of the guided range is $11.15, lower than the Zacks Consensus Estimate for EPS of $11.17. The company’s adjusted EBITDA view for the same period has been reduced to $3.67-$3.70 billion from the $3.71-$3.77 billion provided in the preceding quarter.
RSG’s earnings per share (excluding 1 cent from non-recurring items) of $1.8 outpaced the Zacks Consensus Estimate by 11.7% and grew 17.5% from the year-ago quarter. Revenues of $4.1 billion missed the consensus mark by a slight margin but increased 6.5% on a year-over-year basis.
TRU’s quarterly adjusted earnings (adjusting 69 cents from non-recurring items) of $1 per share surpassed the consensus mark by 2% and increased 14.3% on a year-over-year basis. Total revenues of $1.1 billion outpaced the consensus mark by 2.2% and increased 12% from the year-ago quarter.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
IQVIA Earnings & Revenues Surpass Estimates in Q3, Increase Y/Y
IQVIA Holdings Analytics Inc. (IQV - Free Report) has reported impressive third-quarter 2024 results, wherein earnings and revenues beat the Zacks Consensus Estimate.
See Zacks Earnings Calendar to stay ahead of market-making news.
Adjusted earnings were $2.8 per share, outpacing the Zacks Consensus Estimate by 1.1% and rising 14.1% on a year-over-year basis. Total revenues of $3.9 billion surpassed the consensus estimate by 1.1% and grew 4.3% from the year-ago quarter.
The IQV stock has gained 20% over the past year, underperforming the 30% rally of the industry it belongs to and 39.8% growth of the Zacks S&P 500 Composite.
One Year Price Performance
IQVIA’s Quarterly Details
The Research and Development segment’s revenues were $2.2 billion, increasing 1.9% from the year-ago quarter and 2% on a constant-currency basis. This metric met our estimate.
Revenues from the Technology and Analytics segment were $1.6 billion, increasing 8.6% from the third quarter of 2023. The metric beat our estimate of $1.5 billion and increased 8.2% on a constant-currency basis.
Contract Sales & Medical Solutions revenues decreased 1.6% on a year-over-year basis to $180 million and increased 1.1% on a constant-currency basis. It missed our expectation of $182.9 million.
Adjusted EBITDA for the third quarter of 2024 was $939 million, indicating a 5.7% rise from the year-ago quarter and outpacing our projection of $938.6 million.
The company exited the quarter with cash and cash equivalents of $1.6 billion compared with $1.5 billion at the end of the preceding quarter. Long-term debt (less current portion) was $12.3 billion compared with $12.1 billion at the end of the second quarter of 2024.
Net cash generated from operating activities was $721 million and the capital expenditure for the quarter was $150 million. The company generated a free cash flow of $571 million in the quarter.
IQV’s 2024 Guidance
For 2024, IQVIA lowered its revenue guidance to $15.35-$15.40 billion from the $15.43-$15.53 billion mentioned in the previous quarter. The Zacks Consensus Estimate of $15.46 billion is higher than IQV’s revised guided range.
The company updated the adjusted EPS guidance to $11.10-$11.20 from the $11.10-$11.30 given in the previous quarter. The mid-point of the guided range is $11.15, lower than the Zacks Consensus Estimate for EPS of $11.17. The company’s adjusted EBITDA view for the same period has been reduced to $3.67-$3.70 billion from the $3.71-$3.77 billion provided in the preceding quarter.
IQV carries a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Earnings Snapshot of IQVIA’s Peers
Republic Services, Inc. (RSG - Free Report) reported mixed third-quarter 2024 results.
RSG’s earnings per share (excluding 1 cent from non-recurring items) of $1.8 outpaced the Zacks Consensus Estimate by 11.7% and grew 17.5% from the year-ago quarter. Revenues of $4.1 billion missed the consensus mark by a slight margin but increased 6.5% on a year-over-year basis.
TransUnion (TRU - Free Report) posted impressive third-quarter 2024 results.
TRU’s quarterly adjusted earnings (adjusting 69 cents from non-recurring items) of $1 per share surpassed the consensus mark by 2% and increased 14.3% on a year-over-year basis. Total revenues of $1.1 billion outpaced the consensus mark by 2.2% and increased 12% from the year-ago quarter.